Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich’s Syndrome

Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich’s Syndrome

Gleich’s syndrome (GS) is characterized by recurrent episodes of angioedema, increase in body weight, fever, hypereosinophilia, and elevated serum IgM. The exact etiology remains unclear. Currently, the only treatment strategy is the administration of high dose of steroids during the acute phases. W...

Full description

Bibliographic Details
Main Authors: Andrea Matucci, Francesco Liotta, Emanuele Vivarelli, Laura Dies, Francesco Annunziato, Marie Pierre Piccinni, Francesca Nencini, Sara Pratesi, Enrico Maggi, Alessandra Vultaggio
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-05-01
Series:Frontiers in Immunology
Subjects:
Gleich’s syndrome
mepolizumab
anti-interleukin-5
biological agents
hypereosinophilia
angioedema
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.01198/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.01198/full

Similar Items